
The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

Benefits were also observed among adults aged 18 to 49, with adults over 65 seeing the most benefit.

Research has shown that some receptors for the virus are linked to male hormones.

Patients receiving both IL-6 and corticosteroids showed lower risks of death and mechanical ventilation.

The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.

New study finds differences in testing, disease severity in England.

A single dose of mRNA vaccine proved 81% effective against a SARS-CoV-2 infection.

Testing every 3 days showed a test sensitivity of 98%.

The therapy demonstrated an efficacy of 65.2% against the Delta variant.

A new report suggests a popular sepsis prediction model may not work as well as advertised. The investigator behind the study says there is a need to better understand the inner workings of this and other tools.

New data suggest countries with limited vaccine supplies may not need to immediately vaccinate all members of low-risk households.

Increased respiratory viral testing for COVID-19 and Influenza could have contributed to improved antibiotic prescribing for respiratory symptoms.

Brain tissue in people who died of SARS-CoV-2 look suspiciously like that of people with various forms of dementia and other neurocognitive conditions.

With millions of people facing long-term COVID-19 conditions, the CDC issued interim guidance on evaluation and care.

The COVID-19 pandemic had a substantial effect on women in Kenya who are reliant on transactional sex for income, leading to high levels of food insecurity and psychological burden.

Even if HIV-positive individuals have a low-to-moderate risk for cardiovascular disease, they still experience more coronary plaque.

The activity was higher than what was recently observed for the South African variant.

94% of the participants in the study developed COVID-19 antibodies.

A new Australian study shows the infection rate was 1.61 cases per 1000 people per year over a 3 year study period in participants with access to the therapy.

A group of scientists who published a letter in a French newspaper asked for an inquiry to determine how the virus emerged.

The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.

At the highest dosage, PfSPZ conferred protection for 3 months.

Unvaccinated healthcare workers showed similar levels of antibodies to vaccinated ones.

COVID-19-associated hospitalization of adolescents is more than 12 times less likely than that of adults, but exceeds that associated with influenza by 2.5 to 3 times, the US Centers for Disease Control and Prevention (CDC) reported.

The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.

The Food and Drug Administration (FDA) said the company is concerned about cyclospora contamination on the company’s Dole Fresh Blueberries brand.

A discussion about the Association for Professionals in Infection Control and Epidemiology with CEO Devin Jopp.

Screening and isolation protocols were shown to reduce the risk of transmission.

AFHs reported concerns such as staff coming to work sick and lack of PPE.

IPs experienced PPE shortages, high levels of stress and emotional exhaustion.